These latest guidelines – for healthcare professionals only – define the role of diagnostic and treatment modalities in the management of patients with chronic liver disease.
The following recommendations are defined by internationally recognized scientific organizations and are based on the best available research data and practical experience.
All adults and adolescents (aged ≥12 years) with chronic hepatitis B including pregnant women and girls and women of reproductive age will be eligible for treatment, if they show evidence of significant fibrosis (TE by FibroScan >7 kPa) or cirrhosis (TE by FibroScan >12.5 kPa).
These TE cut-off values (>7 kPa & >12.5 kPa) mentioned at the new WHO guideline 2024 on management of people with CHB infection applied to FibroScan® only.